TNF-α enhances phenotypic and functional maturation of human epidermal Langerhans cells and induces IL-12 p40 and IP-10/CXCL-10 production  by Berthier-Vergnes, Odile et al.
FEBS Letters 579 (2005) 3660–3668 FEBS 29676TNF-a enhances phenotypic and functional maturation of
human epidermal Langerhans cells and induces IL-12 p40 and
IP-10/CXCL-10 production
Odile Berthier-Vergnesa,*, Fabienne Bermonda, Vincent Flacherb,1, Catherine Massacrierb,
Daniel Schmitta, Josette Pe´guet-Navarroa
a Universite´ Claude Bernard Lyon I, EA 37-32, Dermatologie, Hoˆpital Edouard Herriot, Pavillon R, 69437 Lyon Cedex 03, France
b Laboratory for Immunological Research, Schering-Plough Research Institute, Dardilly, France
Received 3 March 2005; revised 7 April 2005; accepted 8 April 2005
Available online 8 June 2005
Edited by Beat ImhofAbstract Dendritic cells (DC) play a central role in immunity/
tolerance decision, depending on their activation/maturation
state. TNF-a is largely produced in the skin under inﬂammatory
conditions. However, it still remains to be deﬁned how TNF-a
modulates the activation status of human LC, the most speciali-
zed DC controlling skin immunity. Here, we reported that fresh
immature LC, highly puriﬁed from healthy human skin and ex-
posed for two days to TNF-a under serum-free conditions, ex-
pressed up-regulated level of co-stimulatory molecules (CD40,
CD54, CD86), maturation markers (CD83, DC-LAMP),
CCR7 lymph node homing receptor, and down-regulated Lang-
erin level, in a dose-dependent manner. This mature phenotype
is closely associated with enhanced LC allostimulatory capacity.
Furthermore, TNF-a signiﬁcantly increased the number of viable
LC and decreased their spontaneous apoptosis. More impor-
tantly, TNF-a induced LC to produce both IFN-gamma-induc-
ible-protein IP-10/CXCL10, a Th1-attracting chemokine and
IL-12 p40. Bioactive IL-12 p70 was never detected, even after
additional CD40 stimulus. The results implicate LC as an eﬀec-
tive target through which TNF-a may up- or down-regulate the
inﬂammatory skin reactions.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Human Langerhans cells; Cytokines; Maturation1. Introduction
Dendritic cells (DC) represent a family of professional anti-
gen-presenting cells that are found in most tissues [1,2]. Lan-
gerhans cells (LC) constitute a special subset of immature
DC, localized in the basal and suprabasal layers of the epider-
mis. They are characterized by the lectin Langerin/CD207, an
endocytic receptor that induces Birbeck granules formation [3].Abbreviations: LC, Langerhans cells; MFI, mean ﬂuorescence inten-
sity; PI, propidium iodide
*Corresponding author. Fax: +33 4 72 11 02 90.
E-mail address: berthier@lyon.inserm.fr (O. Berthier-Vergnes).
1 Present address: Universite´ Claude Bernard, Lyon I, EA 37-32,
Dermatologie, Hoˆpital Edouard Herriot, Pavillon R, 69437 Lyon
Cedex 03, France.
0014-5793/$30.00  2005 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2005.04.087LC play a key role in the initiation of cutaneous immune re-
sponses by capturing and processing foreign antigens and
migrating to the regional lymph nodes where they present
the processed antigen to naive T cells [1,2]. When leaving from
the skin, LC down-regulate Birbeck granules, as well as anchor
receptors, such as E-cadherin, which allows detachment from
the surrounding keratinocytes or the basal lamina [1,2]. Simul-
taneously, chemokine receptors such as CCR7 are induced to
guide the DC through the aﬀerent lymph into the regional
lymph nodes [4]. During this migration, immature LC lose
antigen uptake and processing properties as they diﬀerentiate
into mature cells specialized for T cell stimulation [1,2]. This
process is referred to as DC maturation or activation. Fully
mature DC are recognized by their strong surface expression
of MHC class I/class II, CD54, CD80, CD86, CD40 co-stimu-
latory molecules, CD83 and DC-LAMP maturation markers,
and by their ability to produce pro-inﬂammatory cytokines,
such as bioactive IL-12 p70 [5].
Although LC migration/maturation are crucial biological
events in the initiation of cutaneous immune responses, it is
not yet clear whether they are coordinated or can be induced
independently. However, maturation of peripheral DC repre-
sents a key control point in determining the outcome of im-
mune response. Indeed, while fully mature DC induce
immunity, immature DC, characterized by the lack of co-stim-
ulatory molecules and maturation markers, not only fail to
prime T cells eﬀectively but also serve to promote tolerance
[5,6]. Recently, a third developmental stage of DC maturation
has been proposed: ‘‘semi-mature’’ DC are phenotypically ma-
ture but failed to secrete inﬂammatory cytokines [5].
It is well documented that mobilization of LC to lymph
nodes is triggered by inﬂammatory mediators and especially
TNF-a [7]. The cytokine is largely produced in the skin, mainly
by keratinocytes, in response to various skin infection or injury
[8]. Although TNF-a is a well-known maturation factor for
human DC generated in vitro from cord blood, bone marrow
progenitors, peripheral blood monocytes [2,5], its eﬀect on the
resident epidermal LC has been far less studied. In the murine
system, Koch et al. [9] ﬁrst reported that TNF-a maintains
fresh LC in a viable, but functionally immature state, probably
due to its inability to induce up-regulation of CD86 [10], cru-
cial for eﬀective T-cell stimulation. In this study, we applied a
slight modiﬁcation of a previously described technique [11] to
isolate highly puriﬁed immature LC (>90%) from healthy
human skin. We used these cells as an in vitro system, withblished by Elsevier B.V. All rights reserved.
O. Berthier-Vergnes et al. / FEBS Letters 579 (2005) 3660–3668 3661negligible interference of keratinocyte-derived cytokines, under
serum-free culture conditions, to analyze the activating poten-
tial of TNF-a on their phenotype, function, apoptosis and
cytokine/chemokine secretion.2. Materials and methods
2.1. Culture medium and cytokines
Culture medium was X-VIVO-15 supplemented with 1% gentamycin
(Sigma, St. Louis, MO) and 200 U/ml recombinant human GM-CSF
(speciﬁc activity: 2 · 106 U/mg, a generous gift from Schering-Plough
Research Institute, Kenilworth, NJ), called, thereafter, complete med-
ium. Recombinant human TNF-a (speciﬁc activity 2 · 107 U/mg) was
from Roche Diagnostics (Basel, Switzerland), TGF-b1 (speciﬁc activity
50 · 106 U/mg) from R&D Systems Europe Ltd (Abington, UK) and
interferon-c (speciﬁc activity 4 · 107 U/mg) from Amersham, Les Ullis,
France. Human recombinant IL-10 (speciﬁc activity 2 · 107 U/mg) was
kindly provided by Schering-Plough Research Institute.
2.2. Human epidermal Langerhans cell isolation and culture
LC were highly puriﬁed using a slightly modiﬁed, previously de-
scribed technique [10]. Brieﬂy, epidermal cell suspensions were ob-
tained by trypsinization of human abdominal skin obtained by
plastic surgery (0.05% trypsin, Difco Laboratories, Detroit, MI, 1 h
at 37 C). LC were enriched by three successive density gradient cen-
trifugations on Lymphoprep (Flobio SA, Courbevoie, France). The
resulting population routinely consists of >90% of LC, as assessed
by ﬂow cytometry using anti-HLA-DR-FITC and anti-Langerin-PE.
Highly puriﬁed LC (1 · 106 cells/well) were cultured, or not, for 2 days
in 6-well tissue culture plates (Costar Corp., Cambridge, MA) in com-
plete medium, in the presence or not of TNF-a or IL-10 at diﬀerent
concentrations before carrying out phenotypic and functional assays.
2.3. CD40 ligand-mediated Langerhans cell maturation
Fibroblastic L cells, transfected with the human CD40 ligand
(CD154c) and used for CD40 triggering on human epidermal LC, were
kindly provided by Schering Plough Laboratories (Dardilly, France).
L cells were grown in RPMI 1640 medium supplemented with 10% fe-
tal calf serum and irradiated at 80 Gy before use. 106 puriﬁed LC were
seeded with 105 CD154c onto 24 well cultures plates, in X-VIVO-15
medium supplemented with 2% fetal calf serum (Myoclone, Gibco
BRL Life Technol) and interferon-c (500 U/ml). After two days, LC
were recovered by ﬂushing the plates with RPMI medium and viable
cells were recovered after centrifugation on Lymphoprep before carry-
ing out phenotypic and functional analysis.
2.4. Antibodies and ﬂow cytometry
LC were washed in PBS containing 1% bovine serum albumin, and
incubated for 30 min at 4 C with a panel of FITC- or PE-labeled
mouse mAbs at the appropriate concentration or with irrelevant iso-
type-matched mouse Igs at the same concentration. Cells were washed
and, for indirect staining, further incubated for 30 min at 4 C with
FITC-conjugated FðabÞ02 fragments of goat anti-mouse Ab. The fol-
lowing monoclonal antibodies were used: anti-HLA-DR-FITC
(B8.12.2, IgG2b), anti-CD54-FITC (84H10, IgG1), anti-CD80-FITC
(MAB 104, IgG1), anti-CD83 (HB15A, IgG2b), anti-CD40 (mAb89,
IgG1), anti-Langerin-PE (DCGM4, IgG1), anti-DC-LAMP (104.G4,
IgG1), all from Immunotech (Marseille, France); anti-CD86-FITC
(2331FUN-1, IgG1), anti-CD86-PE (2331FUN-1, IgG1), from BD
Pharmingen (San Diego, CA); anti-CD1a-FITC (NA1/34, IgG2a),
anti-CD1a-PE (NA1/34, IgG2a), anti-CD14-FITC (TUK4, IgG2a)
from Dako (Glostrup, Denmark); anti-CCR6-PE (53103.111, IgG2b)
and anti-CCR7-FITC (150503, IgG2a), anti-TNF-R1-FITC (16803.1,
IgG1) and anti-TNF-R2-FITC (22235.311, IgG2a) from R&D Sys-
tems Europe Ltd (Abington UK). For double labeling, cells were ﬁrst
stained with FITC-conjugated mAbs followed by PE-conjugated anti-
HLA-DR. Intracellular staining for DC-LAMP were carried out by
using the Intrastain Fixperm kit (Dako), according to the manufac-
turers instructions. Analysis of ﬂuorescence staining was performed
with a FACScan ﬂow cytometer (Becton Dickinson, Le Pont de Claix,
France) using the CELLQuest Software. LC population was gated
electronically by cell size and CD1a expression.2.5. Quantiﬁcation of apoptotic Langerhans cells
LC cultured in complete medium with or without diﬀerent concen-
trations of cytokines were evaluated for apoptosis by double staining
with FITC-labeled annexin V and PI according to the manufacturers
recommendations (Annexin V-FITC kit, Immunotech). Sample analy-
sis was performed by ﬂow cytometry, as described above.
2.6. T cell proliferation
Allogeneic T cells were isolated from peripheral blood, by rosetting
with sheep red blood cells as previously described [12]. The T-cell
population contained more than 95% CD3+, as assessed by ﬂow
cytometry. Mixed lymphocyte reactions were carried out in 96-well
round-bottomed plates by adding 105 allogeneic T cells to a graded
number of LC. In some experiments, the cells were previously ﬁxed
(or not) with 1% paraformaldehyde for 30 min on ice. Triplicate cul-
tures were maintained for 5 days at 37 C in a humidiﬁed atmosphere
of 5% CO2. T cell proliferation was assessed at day 5 by addition of
1 lCi of [3H]-methyl-thymidine per well (25 Ci/mmol, Amersham,
Les Ulis, France) for the ﬁnal 18 h of culture. Cells were collected
on glass-ﬁber ﬁlter using a 96-well Harvester (Inotech, Switzerland),
and thymidine incorporation was measured with a direct beta-counter
(Matrix 96, Packard Instrument Co., Meriden, CT). Results were
expressed as the mean cpm ± S.D. of triplicate cultures.
2.7. Cytokine production
Supernatants from cytokine treated or not-treated highly puriﬁed
LC, as well as those of CD40L-activated LC were harvested after
two days, and kept at 80 C before use. The production of IL-1ß,
IL-10 and IL-12 p70 was measured by ELISA using 96-well microtiter
plates (R&D Systems Europe Ltd), according to the manufacturers
instructions: IL-10 (sensitivity: 7.80 pg/ml); IL-12 p70 (sensitivity:
0.625 pg/ml) and IL-1ß (sensitivity: 3.90 pg/ml). Several other cyto-
kines were measured using BD Cytometric Bead Array (BD Biosci-
ences, Mountain View, CA) and LUMINEX Beadlyte cytokine
detection system (Upstate Biotechnology, Lake Placid, NY), according
to the manufacturers protocol. All supernatants were analyzed in
duplicate and results were expressed as the mean amount of cytokine
per ml (pg/ml ± S.D.).
2.8. Statistics
For statistical evaluation of signiﬁcance, the Students t-test was per-
formed. Only P-values less than 0.05 were considered to be signiﬁcant.3. Results
3.1. TNF-a enhances phenotypic maturation of highly puriﬁed
human epidermal LC
We ﬁrst investigated the eﬀect of TNF-a on the phenotypic
maturation of highly puriﬁed human LC (>90% purity) after a
2-day incubation in serum-free medium. IL-10, which is known
to inhibit human LC maturation [10], was used as a negative
control. Fig. 1 illustrates the results of a representative exper-
iment and Table 1 summarizes the results obtained from diﬀer-
ent donors. Freshly isolated LC revealed the typical features of
immature DC, i.e. a lack of CD80, CCR7 and DC-LAMP; low
levels of CD40, CD54, CD83 and CD86; and high levels of
HLA-DR, Langerin, CD1a and CCR6. Upon a 2-day culture
in serum-free medium, human LC up-regulated the expression
of HLA-DR, CD40, CD54, CD83 and CD86, whereas CD1a
and Langerin expression were decreased at the cell surface.
Moreover, CD80, CCR7 and DC-LAMP were induced on epi-
dermal LC, whereas CCR6 was lost.
As shown in Fig. 1 and Table 1, TNF-a clearly enhanced
the expression of most activation and maturation markers in
a dose-dependent way. Especially, CD40, CD54, CD83,
CD86, CCR7 and DC-LAMP were signiﬁcantly upregulated
on LC, as compared to the cells incubated in medium alone
Fig. 1. TNF-a increases phenotypic maturation of human epidermal LC. Human LC were stained with a panel of FITC- or PE-conjugated mAbs
immediately after their isolation from skin samples (fresh LC), or after a 2-day culture in serum-free medium (2 day LC), supplemented or not with
TNF-a at 2.5 (2 day LC, TNF 2.5), 50 ng/ml (2 day LC, TNF 50), or IL-10 at 1.25 ng/ml (2 day LC IL-10). Filled histograms represent speciﬁc and
open histograms isotype-matched control antibodies. Vertical lines correspond to the peak channel of ﬂuorescence intensity of a given antigen on 2-
day LC. The mean ﬂuorescence intensity is reported in each histogram. n.d. not determined. Results are representative of six independent
experiments.
3662 O. Berthier-Vergnes et al. / FEBS Letters 579 (2005) 3660–3668(P < 0.01). Not only was the intensity of the markers in-
creased, but also the percentage of positive cells. By con-
trast, TNF-a signiﬁcantly reduced cell surface Langerin
expression. As expected, LC treatment with IL-10 strongly
decreased the expression of CD40, CD54, CD80, CD86
and DC-LAMP and nearly abolished that of CD83 and
CCR7 (Fig. 1, Table 1). Concurrently, Langerin expression
was clearly upregulated at the cell surface (P < 0.01). Of
note, by contrast with DC generated from CD34+ progeni-
tors [13], IL-10 did not maintain CCR6 expression. These
results showed that TNF-a favors phenotypic maturation
of freshly isolated human LC.
3.2. TNF-a enhances the capacity of human LC to induce
primary allogeneic T cell response
We next determined whether up-regulation of co-stimula-
tory molecules and maturation markers on TNF-a treated
LC might correlate with enhanced antigen-presenting func-
tion. Viable LC, either freshly isolated from skin samples,
or recovered from a 2-day culture in the presence or not of
TNF-a (2.5, 30 and 50 ng/ml) and directly used as antigen-
presenting cells, exhibited similar capacity to stimulate alloge-
neic T cells (not shown). Since LC maturation is known to
occur during the 6-day mixed LC-T cell reaction and may,
therefore, alter the results, LC were ﬁxed with paraformalde-
hyde prior to their addition to the T cells, as previously de-
scribed [14]. As illustrated in Fig. 2, previous TNF-a
exposure strongly enhanced the allostimulatory capacity of
ﬁxed LC, even at low doses (2.5 ng/ml). This eﬀect paralleled
increasing concentrations of the cytokine. Of note is the
inability of ﬁxed fresh LC, as compared with ﬁxed-incubated
LC, to induce T cell proliferation, as previously reported [14].
In agreement with previous data [11], LC incubation with IL-
10 impaired human LC allostimulatory function in a dose
dependent way (not shown).3.3. TNF-a increases the relative number and the maturation
level of a large-sized/HLA-DRhigh/Langerinlow LC subset
As shown in Figs. 1 and 3A, most freshly isolated immature
LC homogeneously stained with anti HLA-DR mAb. By con-
trast, after a 2-day culture, LC comprised two subpopulations
exhibiting either a low or a high HLA-DR ﬂuorescence inten-
sity. Addition of TNF-a signiﬁcantly increased the relative
number of HLA-DRhigh LC (P < 0.001), with a concomitant
decrease in the relative number of HLA-DRlow LC
(P < 0.001), without altering their respective ﬂuorescence
intensity level (Fig. 3A). Thus, in 6 experiments, the mean per-
centage of HLA-DRhigh and HLA-DRlow LC was 54.2 ± 8.2%
and 45.8 ± 13.2% in the control LC suspension, whereas it
averaged 71.1 ± 9.9% and 28.9 ± 10.1% in the TNF-a -treated
(30 ng/ml) LC suspension, respectively. The two LC subsets
could be easily distinguished by their FSC/SSC proﬁles, the
HLA-DRhigh subset exhibiting the largest size (Fig. 3A). Inter-
estingly, Langerin expression was markedly lower in the HLA-
DRhigh than in the HLA-DRlow LC population (Fig. 3A).
We then compared expression of several markers and TNF
receptors on the two LC subpopulations (Fig. 3B). Results
showed that the small-sized/HLA-DRlow LC strongly ex-
pressed Langerin and CD1a but very low levels of most
co-stimulatory molecules, maturation markers and TNF-R2.
Furthermore, CCR6, CCR7 and TNF-R1 were never detected
at the cell surface. Addition of TNF-a did not substantially
alter the results. By contrast, the large-sized/HLA-DRhigh LC
expressed far lower level of Langerin and far higher levels of
co-stimulatory molecules, maturation markers and TNF-R2
(Fig. 3B), while CCR6 and TNF-R1 (not shown) were unde-
tectable. After treatment with TNF-a, the HLA-DRhigh LC
subset showed a clear up-regulation of CD40, CD54, CD83,
CD86, CCR7 and DC-LAMP (Fig. 3B). The TNF-R2 expres-
sion remained unchanged. Collectively, these results show that
TNF-a strongly enhances the relative number and the matura-
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Fig. 2. TNF-a enhances the LC capacity to induce allogeneic T cell
proliferation. Highly puriﬁed LC were ﬁxed with paraformaldehyde
either after their isolation from skin samples (fresh LC), or after 2-day
culture in serum-free medium supplemented or not (0) with TNF-a at
2.5 (TNF 2.5), 30 (TNF 30) or 50 ng/ml (TNF 50). After extensive
washing, LC were enumerated and graded numbers of viable cells were
added to allogeneic T cells. After 5 days, T cell proliferation was
assessed by addition of [3H]-thymidine. Results are expressed as the
mean cpm ± S.D. of triplicate cultures and are representative of 5
separate experiments. T cells alone gave less than 80 cpm.
O. Berthier-Vergnes et al. / FEBS Letters 579 (2005) 3660–3668 3663tion stage of a large sized/HLA-DRhigh/Langerinlow LC sub-
population.
3.4. TNF-a enhances human LC survival by inhibiting apoptosis
of the HLA-DRhigh/Langerinlow LC subset
In all the experiments, TNF-a treatment increased the num-
ber of recovered viable LC (P < 0.001). Indeed, in 6 experi-
ments, the viable cell yield at day 2 averaged 66.9 ± 4.9%
and 75.6 ± 9.1% in the presence of TNF-a at 2.5 and 50 ng/
ml, respectively, whereas it was only 30.2 ± 7.1% in the absence
of the cytokine. To test whether TNF-amight protect LC from
spontaneous apoptosis, we compared the number of apoptotic
cells in the two LC subpopulations, using annexin V-FITC
staining. After a 2-day culture in serum-free medium, apopto-
tic cells were mostly localized in the HLA-DRlow/Langerinhigh
LC population (Fig. 4A). Interestingly, TNF-a decreased the
number of apoptotic cells, in a dose-dependent way. The
results were conﬁrmed using double staining with annexin V-
FITC/propidium iodide (Fig. 4B). As compared to the HLA-
DRhigh, the HLA-DRlow LC population mostly comprised
cells in early and especially late apoptosis. In the presence of
TNF-a, the percentage of viable cells was upregulated in a
dose-dependent way, in the HLA-DRhigh/Langerinlow LC
subset.
3.5. TNF-a induces LC secretion of IP-10 and IL-12 p40
We next examined the eﬀect of TNF-a on the capacity of LC
to produce inﬂammatory cytokines and chemokines. CD40
ligation combined with T cell-derived signals, such as IFN-c,
known to induce maximal cytokines production by DC [15],
was used as a positive control. As shown in Table 2, cultured
LC spontaneously produced high levels of IL-8, minimal levels
Fig. 3. TNF-a promotes the maturation of a high-sized/HLA-DRhigh/Langerinlow LC subset. (A) Isolated human epidermal LC were stained with
FITC-labeled anti-HLA-DR, anti-Langerin or isotype-matched control antibody, either immediately after their puriﬁcation from skin samples
(fresh) or a 2-day culture in serum-free medium supplemented or not (2 day) with TNF-a at 2.5 (2 day, TNF 2.5) or 30 ng/ml (2 day, TNF 30). Cells
were analyzed without any gating. HLA-DR+ LC were subdivided into HLA-DRlow (rectangle) and HLA-DRhigh (oval) subpopulations. (B) Each of
the two HLA-DR subpopulations was gated electronically by cell size (FSC/SSC dot plots) and analyzed independently for expression of various
surface antigens. Filled histograms represent speciﬁc and open histograms isotype-matched control antibodies. Data are representative of six
experiments using skin from diﬀerent donors.
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Fig. 4. TNF-a inhibits apoptosis of the HLA-DRhigh/Langerinlow LC
subset. (A) Fresh LC were seeded in serum-free medium in the absence
(0) or presence of TNF-a at 2.5 (TNF 2.5) or 30 ng/ml (TNF 30) and
analyzed for apoptosis after a 2-day culture. (A) Cells were double
stained with PE-conjugated anti-HLA-DR or anti-langerin, and FITC-
conjugated annexin V and analyzed without any gating. Numbers
represent the percentage of LC in each quadrant. (B) LC apoptosis was
assessed by double staining with annexin V-FITC and propidium
iodide, and each of the two LC subsets were analyzed separately by
gating them according to their size (FSC/SSC). In each dot plot, the
percentage of LC in early apoptosis (Annexin V+/PI: lower right
quadrant), late apoptosis (Annexin V+/PI+ cells: upper right quadrant)
and viable LC (Annexin V/IP: bottom left quadrant) is reported,
and is representative of two separate experiments.
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IL-12 p70. When stimulated with TNF-a, IP-10 and IL-12 p40
were both induced. By contrast, the levels of IL-10, IL-6, IL-12
p70, IL-15 and IL-1ß did not change signiﬁcantly compared
with untreated LC. LC stimulation with CD40L-transfected
cells plus IFN-c resulted in high secretion of IP-10 and IL-12
p40, substantial quantity of IL-6 and IL-10, but few TNF-a
and no IL-12 p70, IL-15 and IL-1ß (Table 2). Interestingly, a
similar cytokine proﬁle was obtained when LC were exposed
to TNF-a, prior to or simultaneously with CD40L + IFN-c
(not shown).
LC stimulated with CD40L + IFN-c exhibited similar typi-
cal mature morphology (e.g. numerous long dendrites) than
those exposed to TNF-a (data not shown). This was conﬁrmed
by phenotypic analysis, showing that CD40L + IFN-c en-
hanced the expression of most activation and maturation
markers in a manner similar to that of TNF-a (not shown),
thus demonstrating the eﬃciency of the stimulus. Although
LC cultures are contaminated by minor numbers of keratino-cytes, their inﬂuence seems rather marginal. Indeed, the ab-
sence of serum leads to a very low level of endogeneous
cytokines, even when stimulated with CD40L + IFN-c (Table
2), except for IP-10.4. Discussion
Recent work has provided deﬁnite evidence for an important
role of DC in immunity and tolerance, depending on their acti-
vation or maturation state. DC maturation is usually induced
by ligands that bind to members of the TNF or toll-like recep-
tor families. Here, we showed that TNF-a exposure of fresh
immature LC, highly puriﬁed from healthy human skin, mark-
edly increased the expression of co-stimulatory molecules
(CD40, CD54, CD86), maturation markers (CD83, DC-
LAMP) and the chemokine receptor CCR7 in a dose-depen-
dent way. This mature phenotype is closely associated with
enhanced LC allostimulating capacity, even at low doses of
TNF-a (2.5 ng/ml). These results contrast with earlier studies
in rodents, showing that TNF-a did not alter allostimulatory
properties [9]. The discrepancy might be explained by species
speciﬁcity or, more likely by the diﬀerences in experimental
conditions, i.e. the LC puriﬁcation yield, the presence or not
of serum during LC cultures and the use of paraformaldehyde
ﬁxed cells in mixed lymphocyte cultures.
Migration of DC from peripheral tissues to lymphoid organs
is a crucial step for their function. This is achieved through the
up-regulation of CCR7, usually attributed to mature DC. We
found that TNF-a strongly increased CCR7 surface expression
on human LC, in a dose dependent way, indicating that TNF-
a -activated LC may migrate into lymph nodes to prime T
cells. Although our data are consistent with the well-known
role of TNF-a in LC departure from epidermis [7], further
studies are needed to determine whether responsiveness to
CCR7 chemokine is functional.
After a 2-day culture, LC matured into two LC subsets,
which could be distinguished by size, co-stimulatory molecules,
maturation markers, and stage of apoptosis. Indeed, the small-
sized/HLA-DRlow/Langerinhigh LC subset likely represents a
dying cell population, as assessed by annexin staining of more
than 80% of the cells (Fig. 4). We showed that TNF-a in-
creased the relative number and the maturation level of the
large sized/HLA-DRhigh/Langerinlow LC subset, a process
partly due to the protective eﬀect of TNF-a against spontane-
ous apoptosis. This is in agreement with previous data demon-
strating that TNF-a maintains the viability of fresh murine LC
[9], emigrated human LC [16], as well as in vitro generated DC
[17].
While TNF-a -induced maturation is mediated exclusively
via TNF-R1 and not TNF-R2 on in vitro generated DC [18],
only TNF-R2 seemed to mediate TNF-a -eﬀects on LC [19],
probably due to the lack [20] or the very low [21] expression
of TNF-R1. Consistent with this, we found that TNF-R2,
but not TNF-R1, was expressed at the surface of both LC sub-
sets, the highest intensity being expressed on the large sized/
HLA-DRhigh/Langerinlow LC subset. It is therefore conceiv-
able that the diﬀerential ability of LC subsets to respond to
maturational and anti-apoptotic TNF-a eﬀects may result
from quantitative diﬀerences in the cell surface expression of
TNF-R2.
Table 2
TNF-a induces IP-10/CXCL-10 and IL-12 p40 secretion by human epidermal LC
No stimulation TNF-a CD40L + IFN-c
LC
Expt 1
IP-10 0 420 >5000
IL-12 p40 0 29.3 99.5
IL-10 3.2 3 60.4
IL-6 9.2 9.7 14.3
IL-12 p70 0 2.7 0
IL-8 >15 000 >15 000 >15 000
IL-15 1.7 1.3 4.7
IL-1SS 3.9 4.1 3.9
TNF-a 5 – 5.1
Expt 2
IP-10 0 84 >5000
IL-12 p40 0 37 130
IL-10 1.8 2.7 9.7
IL-6 5.6 5.5 19.8
IL-12p70 0 0 1.2
IL-8 >15 000 >15 000 >15 000
IL-15 1 1.9 3
IL-1SS 4.2 3.9 3.9
TNF-a 5.4 – 7.5
Expt 3
IP-10 0 459 >10 000
IL-12 p40 9.9 68.5 60.4
IL-10 5.5 6.2 6.8
IL-6 24 34 31
IL-12p70 2.7 5.4 2.1
IL-8 >15 000 >15 000 >15 000
IL-15 2 2.7 2.9
IL-1SS 5.6 5.6 5.7
TNF-a 5.1 – 5.3
Keratinocytes
Expt 1
IP-10 0 37 4355
IL-12 p40 7.9 0 7.9
IL-10 5.4 0 5.4
IL-6 0 0 22.8
IL-12 p70 0 0 1.2
IL-8 1204 3521 2375
IL-15 1.9 1.8 1.8
IL-1SS 5.6 5.6 5.6
TNF-a 5.1 – 5.6
Expt 2
IP-10 0 49.7 n.d.
IL-12 p40 7.9 12.1 n.d.
IL-10 5.4 5.4 n.d.
IL-6 7.4 13.2 n.d.
IL-12p70 0 0 n.d.
IL-8 2530 8886 n.d.
IL-15 1.8 1.8 n.d..
IL-1SS 5.6 5.6 n.d.
TNF-a 5 – 4.9
Expt 3
IP-10 0 55.2 n.d.
IL-12 p40 0 7.9 n.d.
IL-10 5.4 5.4 n.d.
IL-6 8 11.7 n.d.
IL-12p70 0 0 n.d.
IL-8 2852 10 926 n.d.
IL-15 1.8 1.8 n.d.
IL-1SS 5.6 5.7 n.d.
TNF-a 3.8 – 3.6
Highly puriﬁed fresh LC were cultured with TNF-a (30 ng/ml) or CD40 L-transfected
cells combined with of IFN-c (500 U/ml). Pellets of lymphoprep, which consisted
mainly of keratinocytes were cultured in the same way as LC. After 2 days, super-
natants were collected and cytokine concentration was measured by cytometric bead
array assays or ELISA. Results are expressed as pg/ml. n.d.: not determined.
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chemokines is of great importance to amplify and direct the
type of immune response as well as to recruit host immune
eﬀectors [5,6,22,23]. Generally, secretion of the immunostimu-
latory form of IL-12, IL-12 p70 heterodimer consisting of p35
and p40 subunits, is required to induce Th1 responses, whereas
production of IL-10 favors Th2 activation and in some cases
regulatory T cell generation. Some groups have reported that
human LC emigrating from skin explants did not make mea-
surable amounts of bioactive IL-12 p70, even after stimulation
with CD40L ± IFN-c [24,25]. In these situations, LC were ma-
ture at the time of CD40 ligation, which might explain the lack
of cytokine production. Indeed, DC matured by various stim-
uli were unable to produce IL-12 p70 upon subsequent CD40
ligation [22]. Here, we showed for the ﬁrst time that TNF-a
exposure of fresh immature LC induced IL-12 p40, but not
IL-12 p70 secretion, as also reported for in vitro generated
DC [26]. However, whereas CD40 ligation combined with T
cell-derived co-signals, such as IFN-c, triggered full matura-
tion and optimal IL-12 p70 production by monocyte-derived
DC [15], it did not induce human LC to secrete IL-12 p70,
but only its p40 subunit. It is noteworthy that LC generated
in vitro from CD34+ progenitors are also unable to produce
IL-12 p70 after stimulation with CD40L [27], in contrast to
LC generated from monocytes [28].
The failure of human epidermal LC to produce IL-12 p70
has also been observed in response to peptidoglycan, ﬂagellin
and LPS [29]. In agreement with this, we found that strong
IL-12 p70 inducers, including bacterial CpG DNA, viral poly
IC, LPS and combination of CD40L with IL-4, were quite all
unable to induce detectable amounts of Il-12 p70, even after
further ligation with CD40L-transfected cells combined with
IFN-c (manuscript in preparation). The lack of IL-12 p70
could not be related to the assay procedure, since, using the
same method and half lower cell concentration, substantial
amount of IL-12 p70 were found after CD40 cross-linking
of monocyte-derived DC [30]. Furthermore, IL-10, known
to inhibit bioactive IL-12 production by DC [31] was unde-
tectable. Given that IL-12 p40 antagonized IL-12 p70 bioac-
tivity and thus may act in an anti-inﬂammatory manner
[23], it is tempting to speculate that LC themselves can limit
the progression of potentially devastating inﬂammation with-
in the skin.
An important ﬁnding is that TNF-a induces LC to secrete
signiﬁcant levels of IFN-c inducible protein 10 (IP-10/
CXCL10), a chemokine responsible for skin homing of Th1
type lymphocytes [32]. Keratinocytes, which slightly contami-
nate the highly puriﬁed LC, can also produce IP-10 under
TNF-a treatment [33], but in our assays, the data implicate
LC as the main source of the chemokine (Table 2). This could
be related to the serum-free conditions, which was shown to in-
duce a decrease of keratinocyte-derived soluble mediators [34].
IP-10 is largely produced in chronic inﬂammatory diseases
such as psoriasis [35] and the present results suggest that, in
addition to keratinocytes, LC might be involved in the chemo-
kine production. Recently, Fujita et al. [36] reported that exo-
geneous IL-12 could induce IP-10 production by murine LC.
Whether endogeneous IL-12 p40 induced by human LC under
exposure to TNF-amight be responsible for IP-10 secretion re-
mains to be deﬁned. Although the question has not been ad-
dressed here, it would be also of interest to determine the
outcome of T cell response.
O. Berthier-Vergnes et al. / FEBS Letters 579 (2005) 3660–3668 3667In conclusion, our data provide novel information regarding
the eﬀect of TNF-a on human epidermal LC. TNF-a favours
the semi-maturation of LC, characterized by phenotypic mat-
uration but lack of IL-12 p70 production. Furthermore,
through the induction of both IL-12 p40 and IP-10 produc-
tion, TNF-a may confer to human epidermal LC a dual role
in up- or down-regulating the inﬂammatory skin responses.
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